growth hormone secretagogue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Reported for the free peptide |
| Molecular mass | 711.85 Da | Monoisotopic value |
| Residue motif | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Non-natural residues at positions one and three |
| Primary target | GHSR-1a | Ghrelin receptor, G protein coupled |
| Reported plasma half-life | About two hours | Values vary with assay and subject group |
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
By stimulating (or charging) genetically engineered roundworm mitochondria with light, researchers show that halting the decline in mitochondrial membrane potential can slow aging (30 Dec). Researchers report the development of 3D-printed flexible paper-thin organic photovoltaics. 12 December – Scientists describe a new method to break up so-called "forever chemicals" by infusing contaminated water with hydrogen, then blasting it with high-energy, short-wavelength ultraviolet light. 13 December The Newborn Genomes Programme is announced by the UK government. It will conduct whole genome sequencing of 100,000 newborns, the largest study of its kind in the world, to aid research into the diagnosis and treatment of rare genetic conditions. In a major milestone for the field, scientists at the National Ignition Facility report a net energy gain in the development of fusion power. COVID-19 pandemic: A study finds that the BQ and XBB subvariants of SARS-CoV-2 are "barely susceptible to neutralization" by vaccines, including the new Omicron boosters. Key antibody drugs, Evusheld and bebtelovimab, are "completely inactive" against the new subvariants. This could result in a surge of breakthrough infections and reinfections, according to the study team, although the vaccines hold up against severe disease. A study systematically assesses advice given by professional general practitioners, typically in the form of verbal-only consultation, for weight-loss to obese patients.
=== Electrochemical sensors === Electrochemical sensors can be used for label-free sensing of biomolecules. They detect changes and measure current between a probed metal electrode and an electrolyte containing the target analyte. A known potential to the electrode is then applied from a feedback current and the resulting current can be measured. For example, one technique using electrochemical sensing includes slowly raising the voltage causing chemical species at the electrode to be oxidized or reduced. Cell current vs voltage is plotted which can ultimately identify the quantity of chemical species consumed or produced at the electrode. Fluorescent tags can be used in conjunction with electrochemical sensors for ease of detection in a biological system.
Apollo 11 left lunar orbit and returned to Earth, landing safely in the Pacific Ocean on July 24, 1969. When the spacecraft splashed down, 2,982 days had passed since Kennedy's commitment to landing a man on the Moon and returning him safely to the Earth before the end of the decade; the mission was completed with 161 days to spare. With the safe completion of the Apollo 11 mission, the Americans won the race to the Moon. Armstrong and his crew became worldwide celebrities, feted with ticker-tape parades on August 13 in New York City and Chicago, attended by an estimated six million. That evening in Los Angeles they were honored at an official state dinner attended by members of Congress, 44 governors, the Chief Justice of the United States, and ambassadors from 83 nations. The President and Vice president presented each astronaut with the Presidential Medal of Freedom. The astronauts spoke before a joint session of Congress on September 16, 1969. This began a 38-day world tour to 22 foreign countries and included visits with the leaders of many countries. The public's reaction in the Soviet Union was mixed. The Soviet government limited the release of information about the lunar landing, which affected the reaction. A portion of the populace did not give it any attention, and another portion was angered by it. The first landing was followed by another, precision landing on Apollo 12 in November 1969, within walking distance of the Surveyor 3 spacecraft which landed on April 20, 1967.
Disease-modifying antirheumatic drugs (DMARDs), such as hydroxychloroquine and methotrexate, may be used to try to slow the progression of disease. Biological DMARDs may be used when the disease does not respond to other treatments. However, they may have a greater rate of adverse effects. Surgery to repair, replace, or fuse joints may help in certain situations. Rheumatoid arthritis affects about 17.6 million people globally, as of 2020. This is 0.5–1% of adults in the developed world with between 5 and 50 per 100,000 people newly developing the condition each year. Onset is most frequent during middle age and women are affected 2.5 times more than men. It resulted in 38,300 deaths in 2020, up from 28,000 deaths in 1990. The first recognized description of RA was made in 1800 by Dr. Augustin Jacob Landré-Beauvais (1772–1840) of Paris. The term rheumatoid arthritis is based on the Greek words for watery and inflamed joints (from Ancient Greek ῥεῦμα (rheûma) 'flowing current', with arthritis derived from arthr- (meaning 'joint') and -itis (meaning 'inflammation')).
=== Acute toxicity === Melamine is reported to have an oral median lethal dose (LD50) of 3248 mg/kg based on rat data. It is also an irritant when inhaled or in contact with the skin or eyes. The reported dermal LD50 is greater than 1000 mg/kg for rabbits. A study by Soviet researchers in the 1980s suggested that melamine cyanurate, commonly used as a fire retardant, could be more toxic than either melamine or cyanuric acid alone. For rats and mice, the reported LD50 for melamine cyanurate was 4.1 g/kg (given inside the stomach) and 3.5 g/kg (via inhalation), compared to 6.0 and 4.3 g/kg for melamine and 7.7 and 3.4 g/kg for cyanuric acid respectively. A toxicology study in animals conducted after recalls of contaminated pet food concluded that the combination of melamine and cyanuric acid in diet does lead to acute kidney injury in cats. A 2008 study produced similar experimental results in rats and characterized the melamine and cyanuric acid in contaminated pet food from the 2007 outbreak. A 2010 study from Lanzhou University attributed kidney failure in humans to uric acid stone accumulation after ingestion of melamine resulting in a rapid aggregation of metabolites such as cyanuric acid diamide (ammeline) and cyanuric acid. A 2013 study demonstrated that melamine can be metabolized to cyanuric acid by gut bacteria. In particular, Klebsiella terrigena was determined to be a factor in melamine toxicity. In culture, K. terrigena was shown to convert melamine to cyanuric acid directly.
Sources: en.wikipedia.org
== Structure == The human form of IAPP has the amino acid sequence KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY, with a disulfide bridge between cysteine residues 2 and 7. Both the amidated C-terminus and the disulfide bridge are necessary for the full biological activity of amylin. IAPP is capable of forming amyloid fibrils in vitro. Within the fibrillization reaction, the early prefibrillar structures are extremely toxic to beta-cell and insuloma cell cultures. Later amyloid fiber structures also seem to have some cytotoxic effect on cell cultures. Studies have shown that fibrils are the end product and not necessarily the most toxic form of amyloid proteins/peptides in general. A non-fibril forming peptide (1–19 residues of human amylin) is toxic like the full-length peptide but the respective segment of rat amylin is not. It was also demonstrated by solid-state NMR spectroscopy that the fragment 20-29 of the human-amylin fragments membranes. Rats and mice have six substitutions (three of which are proline substitutions at positions 25, 28 and 29) that are believed to prevent the formation of amyloid fibrils, although not completely as seen by its propensity to form amyloid fibrils in vitro. Rat IAPP is nontoxic to beta-cells when overexpressed in transgenic rodents.
Ariel Fernandez (born Ariel Fernández Stigliano, April 8, 1957) is an Argentinian–American physical chemist and pharmaceutical researcher. In 2025, a judge determined that Fernandez had engaged in scientific misconduct, and in 2026 he was barred from receiving federal research funding in the US for 15 years. Fernandez denies the misconduct findings.
== End groups in graft polymers == Graft copolymers are generated by attaching chains of one monomer to the main chain of another polymer; a branched block copolymer is formed. Furthermore, end groups play an important role in the process of initiation, propagation and termination of graft polymers. Graft polymers can be achieved by either "grafting from" or "grafting to"; these different methods are able to produce a vast array of different polymer structures, which can be tailored to the application in question. The "grafting from" approach involves, for example, generation of radicals along a polymer chain, which can then be reacted with monomers to grow a new polymer from the backbone of another. In "grafting from," the initiation sites on the backbone of the first polymer can be part of the backbone structure originally or generated in situ. The "grafting to" approach involves the reaction of functionalized monomers to a polymer backbone. In graft polymers, end groups play an important role, for example, in the "grafting to" technique the generation of the reactive functionalized monomers occurs at the end group, which is then tethered to the polymer chain. There are various methods to synthesize graft polymers some of the more common include redox reaction to produce free radicals, by free radical polymerization techniques avoiding chain termination (ATRP, RAFT, nitroxide mediated, for example) and step-growth polymerization. A schematic of "grafting from" and "grafting to" is illustrated in the figure below.
Antifungals, e.g. ketoconazole. Antibiotics, e.g. erythromycin, rifampicin. Ergot derivatives used to treat migraine or Parkinson's disease may cause an increase in blood pressure. Any potassium-depleting diuretics (medicines for eliminating water), e.g. thiazides. Carbamazepine and phenobarbital, medicines used to control fits or seizures. Herbal medicines that contain St. John's Wort.
Sources: en.wikipedia.org
=== Telechelic oligomer approach === The telechelic oligomer approach applies the usual polymerization manner except that one includes a monofunctional reactant to stop reaction at the oligomer stage, generally in the 50–3000 molecular weight. The monofunctional reactant not only limits polymerization but end-caps the oligomer with functional groups capable of subsequent reaction to achieve curing of the oligomer. Functional groups like alkyne, norbornene, maleimide, nitrite, and cyanate have been used for this purpose. Maleimide and norbornene end-capped oligomers can be cured by heating. Alkyne, nitrile, and cyanate end-capped oligomers can undergo cyclotrimerization, yielding aromatic structures.
== Legacy == After the end of the Cold War in 1991, the assets of the USSR's space program passed mainly to Russia. Since then, the United States and Russia have cooperated in space with the Shuttle-Mir Program, and the International Space Station (ISS). The Russians continue to use their R-7 rocket family as their orbital workhorse to launch the Soyuz crewed spacecraft and its Progress derivative uncrewed cargo craft as shuttles to the ISS. After the 2011 retirement of the Space Shuttle, American crews were dependent on the R-7–Soyuz to reach the ISS, until the 2020 first flight of the US Crew Dragon Commercial Crew Development vehicle. In 2023 the Russian Federation resumed the Luna missions as a part of the Luna-Glob programme with the launch of Luna 25 (47 years after the Soviet Luna 24), amidst American reignition of interest in the Moon with the Artemis program beginning with the launch of Artemis I in 2022. Some of this competitiveness is part of the New Space Race.
Educating patients who have rheumatoid arthritis has shown a positive effect on how patients engage in their plan of care; the patient will be aware of fatigue, activity limitations, and pain and know possible side effects of how to manage this pain. Lack of knowledge can often lead to fear and limit adherence. Intervention by physical therapists plays a key role in offering proper tools for self-management, motivation in activities of daily living, and any assistive device use if needed. Patients will be assisted in managing neurological impairments and musculoskeletal stiffness to maximize strength and function. Encouraging patients to balance physical activity with their everyday living can prevent further joint damage and provide a sense of control. The use of extra-depth shoes and molded insoles may reduce pain during weight-bearing activities such as walking. Insoles may also prevent the progression of bunions.
Sources: en.wikipedia.org
Both molecules activate the same receptor, GHSR-1a, but they share little sequence identity. Ghrelin is a 28-amino-acid hormone carrying a distinctive acyl modification, whereas ipamorelin is a short synthetic peptide. The shared target explains overlapping endocrine effects, while the different structures account for differences in metabolic stability and receptor selectivity.
Early animal and human studies reported growth hormone release at levels that produced small changes in cortisol, prolactin and adrenocorticotropic hormone. That contrast with older secretagogues gave rise to the selectivity label. The observation is consistent across several reports but rests on a limited number of small studies.
Plasma peptidases cleave the molecule into smaller fragments, and reported half-lives in human studies are on the order of a couple of hours. The identity and activity of individual breakdown products have not been fully mapped. Questions about tissue-level clearance remain open.
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.